Relay Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
RLAY$19.94-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Revenue: | |||
| License and other revenue | $25,546 | $1,381 | $3,029 |
| Total revenue | 25,546 | 1,381 | 3,029 |
| Operating expenses: | |||
| Research and development expenses | $330,018 | $246,355 | $172,650 |
| In-process research and development expenses | — | — | 123,000 |
| Loss on initial consolidation of variable interest entity | — | — | 11,855 |
| Change in fair value of contingent consideration liability | (6,422) | (11,677) | 2,836 |
| General and administrative expenses | 74,950 | 65,978 | 57,386 |
| Total operating expenses | 398,546 | 300,656 | 367,727 |
| Loss from operations | (373,000) | (299,275) | (364,698) |
| Other income: | |||
| Interest income | 31,045 | 8,786 | 830 |
| Other expense | (18) | (20) | (4) |
| Total other income, net | 31,027 | 8,766 | 826 |
| Net loss | $(341,973) | $(290,509) | $(363,872) |
| Net loss per share, basic and diluted | $(2.79) | $(2.59) | $(3.82) |
| Weighted average shares of common stock, basic and diluted | 122,576,527 | 112,233,649 | 95,136,719 |
| Other comprehensive loss: | |||
| Unrealized holding gain (loss) | 10,224 | (9,332) | (1,152) |
| Total other comprehensive gain (loss) | 10,224 | (9,332) | (1,152) |
| Total comprehensive loss | $(331,749) | $(299,841) | $(365,024) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.